# **Short Research Article**

# Simple Synthesis of Sulfonyl Amidine-Containing Glucosidase Inhibitors by a Chemoselective Coupling Reaction Between D-Gluconothiolactam and Sulfonyl Azides

## 7

1

2

## 8 ABSTRACT

9

In this report, we describe a simple synthesis of gluconoamidinvlsulfones as a new class of potential inhibitors toward glycan processing enzymes. Gluconoamidinylsulfones have a glucose-based sulfonyl amidine skeleton, thus would form a distorted half-chair conformation with positive charge, which is analogous to transition state in the enzymatic process. A chemoselective coupling reaction between thioamide and sulfonyl azide enabled one-step synthesis of the iminosugar derivatives from commercially D-gluconothiolactam available in а protection-free manner. The phenyl-substituted gluconoamidinylsulfone displayed high inhibitory ability toward  $\alpha$ - and  $\beta$ -glucosidases with  $K_i$  values of 13.9 and 8.2 µM, respectively, resulting that gluconoamidinylsulfones would be expected to entry in a new class of promising potential inhibitors toward various glycan-processing enzymes.

#### 10

13

11 Keywords: inhibitor, glycosidase, iminosugar, coupling reaction, one-step synthesis, thioamide, sulfonyl 12 azide, gluconoamidinylsulfone

#### 14 1. INTRODUCTION

15

16 Iminosugars have been developed as small-molecule inhibitors for various types of glycan processing 17 enzymes [1,2]. These inhibitors are crucial for detailed understanding of glycobiology as well as for development of new promising medicines prescribed in the treatment of diabetes, Gaucher's disease, 18 19 influenza infection, HIV, hepatitis, cancer, etc., involving glycoside-bond cleavage pathway [3]. Chemical 20 structures of glycosidase-inhibiting natural products afford valuable inspirations to design their synthetic 21 analogues. Miglitol [4,5] and miglustat [6,7] are representative therapeutic iminosugars for diabetes and 22 type-1 Gaucher's disease (GD1), respectively, derivatized from a natural glucosidase inhibitor, 1-23 deoxynojirimycin [8] (Fig. 1a). On the other hand, rationally designed iminosugars based on the mechanism of the enzymatic hydrolysis reaction have also been synthesized as candidates of lead 24 25 compounds for glycosidase inhibition [3,9]. A mechanism-based general strategy is transition-state 26 analogue of the enzymatic process. Shape and charge are the key points to mimic the transition state, that is, a partially planar structure in distorted half-chair conformations and delocalized positive charge 27 around the anomeric center of the glycosyl oxocarbenium intermediates (Fig. 1b), the species considered 28 close to the transition state of the hydrolysis process, are important common factors for designing potent 29 30 glycosidase inhibitors. One of the successful inhibitors designed in this way is gluconoamidines (Fig. 1c) that have both a partially flattened geometry and positive charge at a basic amidine center under 31 32 physiological conditions, which exhibited remarkable inhibition abilities toward glycosidases [10,11,12]. 33

34



35 36

37 Fig. 1. Chemical structures of (a) 1-deoxynojirimycin, miglitol, and miglustat, (b) a glycosyl 38 oxocarbenium intermediate. (c) a gluconoamidine (protonation form under physiological 39 conditions), and (d) a gluconoamidinylsulfone (protonation form under physiological conditions)

40

41 We recently reported a chemoselective reaction between thioamides and sulfonyl azides to yield sulfonyl 42 amidines without side reaction even under the coexistence of hydroxyl, amino, and carboxyl groups 43 [13,14] (Scheme 1a). The reaction proceeds in various solvents without any activation additives. In the 44 previous report [13], a six-membered cyclic thioamide, 2-thiopiperidone, with methyl and phenyl sulfonyl 45 azides showed good reactivity in EtOH or H<sub>2</sub>O (Scheme 1b). Inspired by the structural similarity of 2thiopiperidone with iminosugars, we considered that commercially available D-gluconothiolactam would 46 afford sulfonyl amidine derivatives of D-gluconolactam, namely gluconoamidinylsulfones (Figure 1d), by 47 the coupling reaction with sulfonyl azides. Here we report simple synthesis of gluconoamidinylsulfones 1 48 49 and 2 as a new class of potential inhibitors for glycosidase. In addition, conventional inhibitory assay of these compounds toward  $\alpha$ - and  $\beta$ -glucosidases is also described. 50

51 52



53 54

55 Scheme 1. Chemoselective coupling reaction between (a) thioamides and sulfonyl azides in 56 general and (b) 2-thiopiperidone and phenyl sulfonyl azide 57

#### 58 2. MATERIAL AND METHODS

(a)

59

#### 60 2.1 General 61

<sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained at 400 and 100 MHz, respectively, on a JEOL ECX-400P 62 spectrometer. ESI-HRMS analyses were conducted on a JEOL JMS-T100LC mass spectrometer or 63 64 Thermo LTQ Orbitrap XL ETD.

65

#### 66 2.2 Materials

72

74

D-Gluconothiolactam **3** is commercially available but takes long time to arrive, thus **3** was synthesized by simple procedures shown in Scheme 3. D-Gluconolactam **5** [15,16], phenyl sulfonyl azide [14], and mesyl azide [17] were prepared according to literature procedures. Other materials including dehydrate-grade solvents were all commercially available.

#### 73 **2.3 Synthetic procedures**

#### 75 <u>N- Sulfonylphenyl D-gluconoamidine 1</u>

76 77 A 0.5 mL aqueous solution of 3 (6.1 mg, 0.03 mmol) and phenyl sulfonyl azide (30.1 mg, 0.15 mmol) was 78 stirred at 50°C for 24 h. After removal of the solvent, the residue was purified by silica gel PTLC 79 (preparative thin layer chromatography) with a development solvent of  $CHCl_3$ :MeOH = 2:1 to afford 1 as a colorless solid (6.4 mg, 68%). <sup>1</sup>H NMR (400 MHz,  $D_2O$ ):  $\delta$ 7.82 (d, J = 4.0 Hz, 2 H), 7.61–7.48 (m, 3 H), 80 4.01 (d, J = 4.0 Hz, 1 H), 3.85 (dd, J = 12.0, 4.0 Hz, 1 H), 3.63 (t, J = 10.0 Hz, 1 H), 3.52–3.44 (m, 3 H), 81 3.42–3.34 ppm (m, 1 H). <sup>13</sup>C NMR (100 MHz, D<sub>2</sub>O): δ 166.7, 140.3, 134.3, 133.9, 130.1, 126.7, 126.4, 82 83 73.4, 71.7, 68.1, 61.5, 59.5 ppm. ESI-HRMS (*m/z*) calcd for MH<sup>+</sup>, C<sub>12</sub>H<sub>16</sub>N<sub>2</sub>O<sub>6</sub>S: 317.0808; found 84 317.0812. 85

#### 86 <u>N-Sulfonylmethyl D-gluconoamidine 2</u>

87

A 1 mL aqueous solution of **3** (5.8 mg, 0.03 mmol) and mesyl azide (17.8 mg, 0.15 mmol) was stirred at room temperature for 72 h. After removal of the solvent, the residue was purified by silica gel PTLC with a development solvent of CHCl<sub>3</sub>:MeOH = 2:1 to give **2** as a colorless solid (6.2 mg, 82%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O):  $\delta$  4.06 (d, *J* = 8.0 Hz, 1 H), 3.85 (dd, *J* = 12.0, 4.0 Hz, 1 H), 3.69 (t, *J* = 8.0 Hz, 1 H), 3.63 (dd, *J* = 16.0, 4.0 Hz, 1 H), 3.57 (t, *J* = 6.0 Hz, 1 H), 3.42–3.34 ppm (m, 1 H). <sup>13</sup>C NMR (100 MHz, D<sub>2</sub>O):  $\delta$ 166.6, 73.4, 71.6, 68.0, 61.3, 59.6, 41.7 ppm. ESI-HRMS (*m*/*z*) calcd for MH<sup>+</sup>, C<sub>7</sub>H<sub>14</sub>N<sub>2</sub>O<sub>6</sub>S: 255.06516; found 255.0653.

#### 96 2,3,4,6-Tetra-O-(*tert*-butyldimethylsilyl)-D-gluconolactam 6

97

98 A mixture of D-gluconolactam 5 (189 mg, 1.1 mmol), tert-butyldimethylsilyl chloride (TBDMSCI; 1.97 g, 99 12.8 mmol) and imidazole (1.76 g, 25.7 mmol) in anhydrous DMF (2 mL) was vigorously stirred at 0 °C for 100 30 min then at room temperature for 3 days under an argon atmosphere. The mixture was poured into ice 101 water (10 mL) and extracted with Et<sub>2</sub>O (3x15 mL). The combined organic phase was washed with 102 saturated NaCl aqueous solutions (5x15 mL), dried over MgSO<sub>4</sub>. After removal of the solvent, the residue was chromatographed (SiO<sub>2</sub>; eluent, hexane:EtOAc = 5:1) to give **6** (352 mg, 51%) as a colorless solid. 103 104 <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  5.68 (s, 1 H), 3.91 (bs, 1 H), 3.81 (d, J = 4.0 Hz, 1 H), 3.76 (dd, J = 20.0 Hz, 105 4.0 Hz, 1 H), 3.67 (bs, 1 H), 3.55–3.47 (m, 2 H), 0.87–0.80 (m, 35 H), 0.08–0.013 ppm (m, 25H). ESI-106 HRMS (m/z) calcd for MNa<sup>+</sup>, C<sub>30</sub>H<sub>67</sub>NO<sub>5</sub>Si<sub>4</sub>Na: 656.3994; found 656.3982.

107

#### 108 2,3,4,6-Tetra-O-(*tert*-butyldimethylsilyl)-D-gluconothiolactam 7

109

110 A mixture of **6** (352 mg, 0.55 mmol) and Lawesson's reagent (167 mg, 0.41 mmol) in toluene (2.5 mL) 111 was refluxed for 3 h. After removal of the solvent *in vacuo*, the residue was chromatographed (SiO<sub>2</sub>; 112 eluent, hexane:EtOAc = 20:1) to give **7** (288 mg, 80%) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 113  $\delta$  7.90 (s, 1 H), 4.51 (bs, 1 H), 3.90 (dd, *J* = 12.0, 4.0 Hz, 2 H), 3.78 (bs, 1 H), 3.63–3.57 (m, 2 H), 114 0.96–0.86 (m, 36 H), 0.18–0.015 ppm (m, 24 H). ESI-HRMS (*m/z*) calcd for MH<sup>+</sup>, C<sub>30</sub>H<sub>67</sub>NO<sub>4</sub>SSi<sub>4</sub>: 115 650.3947; found 650.3954.

- 116
- 117 D-Gluconothionolactam 3
- 118

<sup>67</sup> 

To a MeOH (6 mL) solution of **7** (153 mg, 0.235 mmol) was added AcCl (221 mg, 2.82 mmol) at room temperature and the reaction mixture was stirred for 6 h at that temperature. After removal of the solvent, the residue was dissolved in water. The aqueous solution was then flushed through a reverse-phase chromatograph cartridge (Mega BE 18C) to give **3** (46 mg, 98%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O):  $\delta$  3.88 (d, *J* = 8.0 Hz, 1 H), 3.77 (dd, *J* = 12.0, 4.0 Hz, 1 H), 3.71 (d, *J* = 8.0 Hz, 1 H), 3.66 (dd, *J* = 120, 4.0 Hz, 1 H), 3.57 (t, *J* = 10 Hz, 1 H), 3.34–3.29 ppm (m, 1 H). <sup>13</sup>C NMR (100 MHz, D<sub>2</sub>O):  $\delta$  204.0, 75.2, 73.4, 68.0, 62.6, 60.2 ppm. ESI-MS (*m/z*) calcd for MH<sup>+</sup>, C<sub>6</sub>H<sub>11</sub>NO<sub>4</sub>S: 194; found 194.

126

#### 127 2.4 Enzymatic assays

128

129 Glucosidase inhibitory assays were carried out for 1, 2, and 1-deoxynojirimycin by means of a 130 conventional spectrometric method [18] at 37 °C using 0.01 M KH<sub>2</sub>PO<sub>4</sub>/K<sub>2</sub>HPO<sub>4</sub> buffer solution (pH 6.8). 131 As a substrate, 4-nitrophenyl- $\alpha$ -glucopyranoside ( $\alpha$ -NGP) toward  $\alpha$ -glucosidase from yeast 132 Saccharomyces cereviceae or 4-nitrophenyl- $\beta$ -glucopyranoside ( $\beta$ -NGP) toward  $\beta$ -glucosidase from 133 sweet almonds was selected. In advance to the assays, stock solutions of enzymes (2U/mL for aglucosidase and 6U/mL for  $\beta$ -glucosidase), substrates (1 mM), and inhibitors (1, 5, 10, 25, 50, 100, and 134 1000  $\mu$ M) were prepared by diluting with the buffer. Mixed solutions of an appropriate amount of  $\alpha$ -NGP 135 136 or  $\beta$ -NGP substrate with various concentrations of each inhibitor solution were poured in cells of a 96-well 137 microplate. Addition of the enzyme solution to the cells immediately progressed the enzymatic reaction, 138 affording 4-nitrophenolate anion as a cleavage product that can be monitored at 405 nm of absorbance by a microplate reader (FilterMax F5<sup>™</sup>). The absorption data were simultaneously collected from 1 to 25 139 min at 2 min intervals. In these assays, the final concentrations of the substrates were 16.7, 33.3, 50.0, 140 141 66.7, and 83.3  $\mu$ M for  $\alpha$ -glucosidase whereas 30.0, 60.0, 90.0, 120, and 150  $\mu$ M in absence or presence 142 of the inhibitors. The inhibition constants ( $K_i$ ) were determined by using the slopes of Lineweaver–Burk 143 plots and double reciprocal analysis. All experiments were conducted in duplicate and obtained data were 144 averaged.

145

#### 146 3. RESULTS AND DISCUSSION

147

148 One-step syntheses of gluconoamidinylsulfones 1 and 2 were performed by simply mixing of commercially available D-gluconothiolactam 3 with phenyl sulfonyl azide or mesyl azide in water (Scheme 149 2). The reaction mixture was vigorously stirred for an appropriate reaction time, affording 150 151 gluconoamidinylsulfones 1 and 2 in 68% and 86% isolated yields, respectively. These compounds were characterized by means of <sup>1</sup>H NMR, <sup>13</sup>C NMR and ESI-HRMS (electrospray ionization high resolution 152 153 mass spectrometry). Because regio- and stereoselective sugar derivatization generally tends to be a 154 complicated multistep synthesis involving protection and deprotection steps, it is noteworthy that, by using 155 this coupling reaction, one-step synthesis in a protection-free manner generated a new class of potential 156 inhibitors directly. 157



158 159

160 Scheme 2. Protection-free, one-step synthesis of gluconoaminidylsulfones 1 and 2 by the 161 coupling reaction

162 163

D-gluconothiolactam **3** is commercially available, however, it seems to take about two months to arrive. Thus, we prepared **3** separately according to literature procedures [10,15,16] with minor modification

# UNDER PEER REVIEW

(Scheme 3). Gluconolactam 5 was initially synthesized from a readily purchasable 4 in a manner similar
to those reported [15,16]. Unfortunately, direct thioamidation of 5 by Lawesson's reagent (LR) was failed
to produce 3. Silylation of 5 with TBDMSCI followed by thioamidation with LR was a successful route,
affording a thiolactam derivative 7. Removal of the silyl-protection with AcCl in MeOH generated Dgluconothiolactam 3 quantitatively.

171 172



173 174

#### 175 Scheme 3. Synthesis of D-gluconothiolactam

176 Reagents and reaction conditions: (a) TBDMSCI, imidazole, dry DMF, rt, 3 days, 51%, (b) Lawesson's reagent, 177 toluene, reflux, 3 h, 80%, (c) AcCl, MeOH, rt, 6 h, 98%.

178 179

180 Next, enzymatic assay was performed for gluconoamidinylsulfones toward glucosidases by means of a conventional spectroscopic methodology with 4-nitrophenyl  $\alpha$ - or  $\beta$ -glucopyranoside as a substrate. Table 181 182 1 shows the inhibitory ability of gluconoamidinylsulfones 1 and 2 against  $\alpha$ -glucosidase from yeast S. cereviceae (E.C. 3.2.1.20) and  $\beta$ -glucosidase from almonds (E.C. 3.2.1.21). In advance, trial assays were 183 conducted by using 1-deoxynojirimycin, which displayed the inhibition constant  $K_i$  of 24.5  $\mu$ M for 184 185  $\alpha$ -glucosidase and 28.1  $\mu$ M for  $\beta$ -glucosidase. Although multiple  $K_i$  values have been reported for 1deoxynojirimycin toward the glycosidases under the different measurement setup [1,8], the obtained  $K_i$ 186 187 values in this study fall within the range of values, indicating that our assay condition and analysis procedure would be appropriate and reliable. Phenyl-substituted 1 exhibited strong inhibition against both 188 189  $\alpha$ - and  $\beta$ -glucosidases with K of 13.9 and 8.2  $\mu$ M, respectively, being more high inhibitory ability than that of 1-deoxynojirimycin. On the other hand, methyl-substitution showed weak inhibition against both  $\alpha$ - and 190 191 β-glucosidases.

192

#### 193 194

195

#### Table 1. Inhibition constants of 1 and 2 toward $\alpha$ - and $\beta$ -glucosidases

Inhibitors  $K_{i}$  for  $\alpha$ -glucosidas<sup>a</sup> ( $\mu$ M)  $K_i$  for  $\beta$ -glucosidas<sup>b</sup> ( $\mu$ M) 0, 8.2 HO 13.9 HO нò 1 OH HO HO >1000 764 2



197 Glycosyl hydrases have several subsites in their binding pocket such as glycon and aglycon binding sites 198 [18]. The adjycon subsites are usually made up of several hydrophobic residues such as phenylalanine. 199 tyrosine, and tryptophan surrounding a ligand saccharide. Therefore, as an old trick, connecting a 200 hydrophobic glycon analogue to aglycon mimics like iminosugars has been used for glycol-modification 201 [19,20]. The strong glucosidase inhibition of the gluconoamidinylsulfone 1 seemly caused by the aglycon 202 phenyl-group that might fit with the aglycon subsite of  $\alpha$ - and  $\beta$ -glucosidases. From the analysis of amino 203 acid sequence and three-dimensional structure, there are several phenylalanine residues around aglycon 204 subsite of glucosidases [21]. In addition to the geometrically and electrostatically well-fitting of the 205 gluconoamidine skeleton at the glycon subusite, hydrophobic and  $\pi$ - $\pi$  interactions at the aglycon site 206 might affect effectively, at least in part, to the inhibition activity of phenyl-substituted 1, while the methyl 207 group in 2 exhibited weak interaction with the subsite. Although only two gluconoamidinylsulfones and glycosidases were used in this report, the results indicate that further study may reveal the potential of 208 209 this skeleton as a new class of inhibitors toward various glycan processing enzymes such as 210 mannosidases, galactosidases, and transferases, by taking advantage of the simple synthetic approach. 211

### 212 **4. CONCLUSION**

213

223

The chemoselective coupling reaction of D-gluconothiolactam and sulfonyl azides successfully generated gluconoamidinylsulfones in a simple synthetic manner. The phenyl-substituted gluconoamidinylsulfone showed high inhibitory ability toward  $\alpha$ - and  $\beta$ -glucosidases so that gluconoamidinylsulfones would be expected to entry in a new class of promising potential inhibitors toward various glycosidases. Making the best use of the synthetic advantage, expansion of the compound library of gluconoamidinylsulfones and the following enzyme assays toward wide variety of glycosyl hydrases and transferases are currently in progress.

#### 222 **REFERENCES**

- Stütz AE, editor. Iminosugars as Glycosidase Inhibitors: Nojirimycin and Beyond. Weinheim: WILEY VCH; 1999.
- 227 2. Gloster TM, Vocadlo DJ. Developing Inhibitors of Glycan Processing Enzymes as Tools for Enabling
   228 Glycobiology. Nat Chem Biol. 2012;8(8):683-94.
   229
- 3. Gloster TM, Davis DJ. Glycosidase Inhibition: Assessing Mimicry of the Transition State. Org Biomol
  Chem. 2010;8(2):305-20.
- 4. Scott LJ, Spencer CM. Miglitol: A Review of its Therapeutic Potential in Type 2 Diabetes Mellitus.
  Drygs. 2000;59(3):521-49.
- 5. Sugimoto S, Nakajina H, Kosaka K, Hosoi H. Review: Miglitol has Potential as a Therapeutic Drug
  Against Obesity. Nutr Metab. 2015;12:51.
- 6. Smid BE, Hollak CEM. A Systematic Review on Effectiveness and Safety of Eliglustat for Type 1
  Gacher Disease. Expert Opin Orphan Drugs. 2014;2(5):523-9.
- 242 7. Lyseng-Williamson KA. Miglustat: A Review of Its Use in Niemann-Pick Disease Type C. Drygs.
  243 2014;74(1):61-74.
  244
- 245 8. Hughes AB, Rudge AJ. Deoxynojirimycin: Synthesis and Biological Activity. Nat Prod Rep. 246 1994;11(2):135-62.
- 247
  248 9. Ganem B, Papandreou G. Mimicking the Glucosidase Transition State: Shape/Charge Considerations.
  249 J Am Chem Soc. 1991;113(23):8984-5.
- 250

# UNDER PEER REVIEW

- 10. Tong MK, Papandreou G, Ganem B. Potent, Broad-Spectrum Inhibition of Glycosyntheses by an
  Amidine Derivative of D-Glucose. J Am Chem Soc. 1990;112(16):6137-9.
- 11. Papandreou G, Tong MK, Ganem B. Amidine, Amidrazone, and Amidoxime Derivatives of
   Monosaccharide Aldonolactams: Synthesis and Evaluation as Glycosidase inhibitors. J Am Chem Soc.
   1993;115(25):11682-90.
- 12. Heck M-P, Vincent SP, Murray BW, Bellamy F, Wong C-H, Mioskowski C. Cyclic Amidine Sugars as
  Transition-State Analogue Inhibitors of Glycosidases: Potent Competitive Inhibitors of Mannosidases. J
  Am Chem Soc. 2004;126(7):1971-9.
- 13. Aswad M, Chiba J, Tomohiro T, Hatanaka Y. Coupling Reaction of Thioamides and Sulfonyl Azides:
  An Effective Catalyst-Free Click-Type Ligation under Mild Conditions. Chem Commun.
  2013;49(87):10242-4.
- 14. Aswad M, Chiba J, Tomohiro T, Hatanaka Y. Evaluation of Dipole Moment and Electrophilicity on the
   Nature of Click-Type Coupling Reaction Between Thioamide and Sulfonyl Azide. Tetrahedron Lett.
   2016;57(12):1313-6.
- 269
  270 15. Li T, Guo L, Zhang Y, Wang J, Zhang Z, Li J, et al. Structure-Activity Relationships in aSseries of C2271 Substituted Gluco-Configured Tetrahydroimidazopyridines as β-Glucosidase Inhibitors. Bioorg Med
  272 Chem. 2011;19(7):2136-44.
  273
- 16. Overkleeft HS, Wiltenburg JV, Pandit UK. A Facile Transformation of Sugar Lactones to Azasugar.
  Tetrahedron. 1994;50(14):4215-24.
- 277 17. Danheiser RL, Miller RF, Brisbois RG, Park SZ. An Improved Method for the Synthesis of α-Diazo
  278 Ketones. Clin Exp Allergy. 2002;32(4):489-98.
- 279
  280 18. Davies GJ, Wilson KS, Henrissat B, Park SZ. Nomenclature for Sugar-Binding Subsites in Glycosyl
  281 Hydrases. Biochem J. 1997;321(2):557-9.
- 19. Yuasa H, Saotome C, Kanie O. Design Syntheses of Inhibitors of Glycoenzymes. Trends Glycosci
   Glycotechnol. 2002;14(78):231-51.
- 286 20. Hakamata W, Kurihara M, Okuda H, Nishio T, Oku T. Design and Screening Strategies for α 287 Glucosidase Inhibitors Based on Enzymological information. Curr Top Med Chem. 2009;9(1):3-12.
- 288
  289 21. Tagami T, Yamashita K, Okuyama M, Mori Haruhide, Yao Min, Kimura A. Molecular Basis for the
  290 Recognition of Long-Chain Substrates by Plant α-Glucosidases. J Biol Chem. 2013;288(26):19296-303.
  291
- 292

282

285